AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
Log in

OTCMKTS:ARGSQArgos Therapeutics Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
$0.05
MA: $0.05
$0.05
52-Week Range N/A
VolumeN/A
Average Volume3,250 shs
Market Capitalization$572,000.00
P/E RatioN/A
Dividend YieldN/A
Beta2.47
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.
Read More
Argos Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ARGSQ
CUSIPN/A
Phone919-287-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.90 million
Book Value($1.63) per share

Profitability

Miscellaneous

Employees21
Market Cap$572,000.00
Next Earnings DateN/A
OptionableNot Optionable

Receive ARGSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGSQ and its competitors with MarketBeat's FREE daily newsletter.

Argos Therapeutics (OTCMKTS:ARGSQ) Frequently Asked Questions

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc (OTCMKTS:ARGSQ) posted its quarterly earnings data on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($4.50) by $0.30. The biopharmaceutical company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.10 million. View Argos Therapeutics' earnings history.

When did Argos Therapeutics' stock split? How did Argos Therapeutics' stock split work?

Shares of Argos Therapeutics reverse split before market open on Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of Argos Therapeutics stock prior to the reverse split would have 5 shares after the split.

Has Argos Therapeutics been receiving favorable news coverage?

News articles about ARGSQ stock have trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Argos Therapeutics earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutArgos Therapeutics.

Who are some of Argos Therapeutics' key competitors?

Who are Argos Therapeutics' key executives?

Argos Therapeutics' management team includes the following people:
  • Dr. Charles A. Nicolette, Consultant (Age 57)
  • Mr. Jeffrey D. Abbey, Consultant & Director (Age 57)
  • Dr. Richard D. Katz, Consultant (Age 55)
  • Ms. Lori R. Harrelson CPA, CPA, VP of Fin. (Age 50)
  • Mr. William N. Wofford, Sec.

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the OTCMKTS under the ticker symbol "ARGSQ."

How do I buy shares of Argos Therapeutics?

Shares of ARGSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Argos Therapeutics?

Argos Therapeutics has a market capitalization of $0.00 and generates $1.90 million in revenue each year. Argos Therapeutics employs 21 workers across the globe.

What is Argos Therapeutics' official website?

The official website for Argos Therapeutics is www.argostherapeutics.com.

How can I contact Argos Therapeutics?

Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The biopharmaceutical company can be reached via phone at 919-287-6300.

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.